Physician profile
Brook L Brouha
NPI 1114173937
$20,064.44
in general payments reported to CMS, 2019-2025
39 companies · $3,886 in 2025
The $3,886 reported for 2025 was more than what 93% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,827 · 2020: $1,100 · 2021: $1,753 · 2022: $2,258 · 2023: $5,662 · 2024: $3,578 · 2025: $3,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $2,250 · Education: $710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,166.08 |
| Consulting Fee | $2,250.00 |
| Education | $709.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $2,666.00 | 2023-2025 | Zoryve |
| Abbvie INC. | $2,384.70 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Janssen Biotech, INC. | $1,528.70 | 2019-2025 | Tremfya, Stelara, Remicade |
| Pfizer INC. | $1,460.80 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,336.45 | 2019-2025 | Winlevi, Ilumya, Absorica Ld |
| Incyte Corporation | $1,231.29 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $1,172.58 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $1,160.51 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $989.44 | 2019-2025 | |
| Leo Pharma INC. | $936.85 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Novartis Pharmaceuticals Corporation | $740.64 | 2019-2025 | |
| Galderma Laboratories, L.P. | $633.50 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Ucb, INC. | $629.60 | 2020-2025 | Bimzelx, Cimzia |
| Amgen INC. | $538.49 | 2021-2025 | Otezla, Otezla |
| Biofrontera INC. | $301.22 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brook Brouha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.